Topic
FP Regimen
About: FP Regimen is a research topic. Over the lifetime, 26 publications have been published within this topic receiving 492 citations.
Papers
Journal Article•
TL;DR: DCF induction chemotherapy may be an option for conversion therapy of initially unresectable, locally advanced esophageal cancer and result in increased postoperative complications compared to the FP regimen.
Abstract: Background: This study aimed to evaluate the efficacy of docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline- resectable T4 esophageal cancer. Patients and Methods: We retrospectively analyzed data regarding thirty patients with borderline-resectable T4 tumor who received either DCF or cisplatin plus 5-fluorouracil (FP) as induction chemotherapy. Results: The overall response rate was significantly better for the DCF group than the FP group. In the DCF group, 6/16 patients achieved a grade 2 histological post- chemotherapeutic effect after treatment, compared to 1/14 in FP group. Except for myelotoxicity, no other significant differences in toxicity were observed during induction chemotherapy between groups. The DCF regimen did not result in increased postoperative complications compared to the FP regimen. Postoperative recurrence or distant metastasis was observed in 7/10 of FP patients and 5/12 of DCF patients. Conclusion: DCF induction chemotherapy may be an option for conversion therapy of initially unresectable, locally advanced esophageal cancer. Surgical treatment with three-field lymph node dissection has contributed to improvement in the survival rates of advanced esophageal cancer patients (1, 2). However, analyses of disease recurrence patterns after surgery alone have suggested that surgery alone was insufficient for local control, and have prompted the addition of adjuvant radiotherapy, chemotherapy, or chemoradiotherapy. The introduction of these types of multidisciplinary treatments is thought necessary to improve outcome, especially in advanced esophageal cancer. Western and Japanese physicians have very different opinions of the roles of chemotherapy and radiotherapy in achieving local control. Based on several clinical trials assessing the effectiveness of neoadjuvant chemoradiotherapy, patients with resectable but advanced squamous cell carcinoma (SCC) of the esophagus usually receive preoperative chemoradiotherapy in Western countries. However, in Japan, there have not been any randomized controlled studies to evaluate the clinical significance of preoperative chemoradiotherapy. After the results of the Japan Clinical Oncology Group (JCOG) 9907 study were reported, neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil (FP) followed by surgery emerged as a new standard treatment for clinical stage II or III esophageal cancer in Japan (3). However, patients with unequivocal T4 disease were excluded from this study, and many Japanese institutions exclude T4 disease as an indication for surgery. In patients with T4 tumors and/or M1 lymph node metastasis, chemoradiotherapy with FP is considered standard treatment (4). At our institution, we have sometimes seen patients with locally advanced esophageal cancer suspected of invading adjacent organs, but not definitively diagnosed as T4 disease. We called these cases 'borderline-resectable T4' cancer. A recent controlled study at an experienced center demonstrated a 2-year survival of around 52% for patients with locally advanced SCC of the esophagus (T3-T4N0-N1) who received neoadjuvant chemoradiotherapy followed by surgery (5), in contrast to the 40% survival for similar patients receiving chemoradiotherapy alone reported in a multicenter trial by Bedenne and co-workers (6). This survival difference suggests that the addition of surgery to chemoradiotherapy for locally advanced SCC can result in
58 citations
TL;DR: GP regimen with superior efficacy was proved to be more cost-effective than the traditional FP regimen and it is likely that GP regimen may be recommended as the primarily first-line treatment option for recurrent or metastatic nasopharyngeal carcinoma.
19 citations
TL;DR: The radiologic features of PALN, such as number or size, can be used to determine prognosis in PALN metastatic cervical cancer patients and FP regimen concurrent chemoradiotherapy was associated with better patient survival than radiotherapy alone.
Abstract: OBJECTIVE The purpose of the present study was to evaluate treatment outcomes and prognostic factors in cervical cancer patients with isolated para-aortic lymph node (PALN) metastases. We especially tried to evaluate PALN factors such as size, site and number. METHODS From August 1994 to December 2009, 40 cervical cancer patients with isolated PALN node metastases at initial diagnosis were selected for analysis. Patients underwent both extended field external beam and intracavitary brachytherapy. Fourteen patients received 5-fluorouracil and cisplatin (FP) and 16 patients received weekly concurrent cisplatin. Information of PALN, such as size, site, and number, was founded before PALN radiotherapy. RESULTS The median follow-up time after primary treatment was 28.5 months (range, 2 to 213 months). The 3-year overall and progression-free survival rate after primary treatment was 44.3% and 31.3%, respectively. In multivariate analysis including tumor stage, performance status, and chemotherapy, FP regimen concurrent chemoradiotherapy was more effective than radiotherapy alone (p=0.030). The 3-year progression-free survival rate was 41.9% and 11.1% in patients with PALN numbers of ≤1 and ≥2, respectively (p=0.008). The 3-year progression-free survival rate was 42.1% and 19.2% in patients with PALN size of <1.5 cm and ≥1.5 cm, respectively (p=0.031). CONCLUSION The radiologic features of PALN, such as number or size, can be used to determine prognosis in PALN metastatic cervical cancer patients. Furthermore, FP regimen concurrent chemoradiotherapy was associated with better patient survival than radiotherapy alone. However, more studies are required to confirm possible different treatment outcomes between FP and weekly cisplatin regimens.
17 citations
TL;DR: GP regimen may be superior to TP/FP regimen (fluorouracil + cisplatin) in treating locoregionally advanced NPC and had a trend toward improved DMFS.
Abstract: OBJECTIVE: To investigate the outcome of locoregionally advanced nasopharyngeal carcinoma (NPC) treated with induction chemotherapy followed by chemoradiotherapy.
METHODS: Between June 2005 and October 2007, 604 patients with locoregionally advanced NPC were analyzed, of whom 399 and 205 were treated with conventional radiotherapy and intensity-modulated radiotherapy (IMRT) respectively. Meanwhile, 153 patients received concurrent chemotherapy, and 520 were given induction chemotherapy.
RESULTS: With a median follow-up time of 65 months, the 3-, and 5-year overall survival (OS), locoregional free survival (LRFS), and distant-metastasis free survival (DMFS) rates were 82.5% vs. 72.6%, 90.6% vs. 87.1%, and 82.5% vs. 81.2%, respectively. Induction chemotherapy was not an independent prognostic factor for OS (P=0.193) or LRFS, but there was a positive tendency for DMFS (P=0.088). GP regimen (gemcitabine + cisplatin) was an independent prognostic factor for OS (P = 0.038) and it had a trend toward improved DMFS (P = 0.109). TP regimen (taxol + cisplatin) was only a significant prognostic factor for DMFS (P =0.038).
CONCLUSIONS: Adding induction chemotherapy had no survival benefit, but GP regimen benefited overall survival and had a trend toward improved DMFS. GP regimen may be superior to TP/FP regimen (fluorouracil + cisplatin) in treating locoregionally advanced NPC.
15 citations
TL;DR: The authors' protocol of the cisplatin-based concurrent CRT followed by adjuvant chemotherapy consisting of FP regimen was effective for Japanese patients with NPC, however, the doses and numbers of cycle of chemotherapy need to be modified because of the low compliance rate.
Abstract: (80 mg/m 2 ) were scheduled during 70 Gy of radiotherapy (RT), and two agents of adjuvant chemotherapy (FP regimen: cisplatin 80 mg/m 2 and 5-fluorouracil 800 mg/m 2 /day by 4-day continuous infusion) were challenged. Overall survival (OS) and relapse-free survival (RFS) rates were calculated by the Kaplan–Meier method. Results: Median follow-up duration was 45 months. Both 3-year OS and RFS rates were 81%. Proportions of patients who tolerated each scheduled treatment were 94% for RT, 63% for concurrent chemotherapy and 38% for adjuvant chemotherapy. Conclusions: Our protocol of the cisplatin-based concurrent CRT followed by adjuvant chemotherapy consisting of FP regimen was effective for Japanese patients with NPC. However, the dosesandnumbersofcycleofchemotherapyneedtobemodifiedbecauseofthelowcompliance rate. Larger numbers of data accumulation and/or multi-institutional trials may be warranted to confirm the efficacy of this protocol.
9 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 1 |